Azitra Expands ATR-04 Clinical Trial to MD Anderson Cancer Center for EGFR Inhibitor-Associated Rash Treatment
核心洞察
Azitra has added MD Anderson Cancer Center as the sixth clinical site for its Phase 1/2 trial of ATR-04, a live biotherapeutic targeting EGFR inhibitor-associated rash (搜索) affecting up to 80% of patients on EGFR (搜索) therapies.
The company's ATR-04 program has received FDA Fast Track designation and targets approximately 150,000 patients annually in the United States who experience this treatment-limiting side effect.
Azitra anticipates topline data from the first cohort of the Phase 1/2 trial around mid-2026, with the study currently enrolling eight patients in Cohort 1.
Azitra, Inc. (搜索) has announced the addition of The University of Texas MD Anderson Cancer Center as a clinical site for its ongoing Phase 1/2 clinical trial evaluating ATR-04, a first-in-class topically applied live biotherapeutic product candidate designed to treat EGFR inhibitor-associated rash (搜索). The expansion brings the total number of clinical sites to six for this pivotal study.
Addressing a Critical Unmet Medical Need
EGFR inhibitor-associated rash (搜索) represents a significant clinical challenge, affecting up to 80% of patients receiving EGFR (搜索) inhibitor therapies. This major side effect frequently leads to treatment interruptions or discontinuations, potentially compromising cancer treatment outcomes. The condition affects approximately 150,000 patients annually in the United States, representing a substantial unmet medical need in oncology supportive care.
"As a leading cancer site that treats thousands of patients a year, oncologists at MD Anderson understand the impact of EGFRi-associated rash," said Francisco Salva, CEO of Azitra. "As this major side effect frequently leads to treatment interruptions or discontinuations, the field is in need of innovative solutions like ATR-04, a topically applied product with the potential to help patients stay on their primary cancer treatments."
Clinical Trial Design and Objectives
The multicenter, randomized, double-blind, vehicle-controlled Phase 1/2 clinical study (NCT06830863) is designed to evaluate the safety and tolerability of topical ATR04-484 for the treatment of EGFRi-associated dermal toxicity affecting the face of adult patients. The study employs a 3:1 randomization ratio, with ATR04-484 or its vehicle applied to the face as well as affected areas on the neck, chest, back, and areas around nailbeds.
The key objectives include assessing the safety and tolerability of topical ATR04-484 and evaluating early efficacy signals. The study is currently enrolling patients for Cohort 1, which is anticipated to enroll a total of eight patients. Topline data from the first cohort is expected around mid-2026.
Innovative Mechanism of Action
ATR04-484 is a live biotherapeutic product candidate featuring an isolated, naturally derived Staphylococcus epidermidis strain specifically developed for EGFRi-associated skin rash. The candidate was selected based on its preclinical profile of reducing IL-36γ (搜索) and Staphylococcus aureus levels, both of which are elevated in patients with EGFRi-associated skin rash.
The strain has been engineered for safety by deleting an antibiotic resistance gene and engineering auxotrophy to control the growth of ATR04-484. Preclinical data demonstrate that ATR-04 can reduce levels of IL-36γ (搜索), a key pro-inflammatory cytokine elevated in these rashes. Additionally, ATR-04 has shown the ability to inhibit the growth of S. aureus in preclinical studies, which often colonizes the skin of affected patients.
Regulatory Recognition and Pipeline Progress
The FDA has granted Fast Track designation to ATR-04 for the treatment of EGFRi-associated rash, recognizing the high unmet medical need for this patient population. This designation is expected to facilitate more frequent communication with the FDA and potentially expedite the review process.
Beyond ATR-04, Azitra's pipeline includes ATR-12, the company's lead program targeting Netherton syndrome (搜索), a rare chronic skin disease with no approved treatment options. In June 2025, Azitra reported promising safety data with 50% of patients enrolled in the Phase 1b trial. The ATR12-351 candidate has been generally safe and well-tolerated with occasional, transient, mild to moderate symptoms at the application site. Topline data from the Phase 1b trial is anticipated in H2 2026.
Financial Position and Future Outlook
For the year ended December 31, 2025, Azitra reported research and development expenses of $4.8 million compared to $4.7 million in 2024, while general and administrative expenses were $6.2 million compared to $6.3 million in 2024. The company reported a net loss of $11.0 million for 2025 compared to $9.0 million in 2024, with cash and cash equivalents of $2.1 million as of December 31, 2025.
The company's proprietary platform encompasses engineered proteins and topical live biotherapeutic products, including a microbial library comprised of approximately 1,500 bacterial strains. This platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the library of strains for drug-like molecules.
Looking ahead, Azitra anticipates several key milestones in 2026, including topline data for both the Phase 1b study in Netherton syndrome (搜索) and the Phase 1/2 study in EGFRi-associated rash, as well as completing IND-enabling studies for ATR-01, which targets ichthyosis vulgaris (搜索) affecting 1.3 million people in the United States.